What is DBD's health score?

DIEBOLD NIXDORF, Inc (DBD) has a TradeApes health score of 60 out of 100, rated Healthy. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is DBD's estimated fair value?

Based on our 5-year discounted cash flow model, DIEBOLD NIXDORF, Inc's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is DBD undervalued or overvalued?

Our model currently rates DBD as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for DBD... Refresh in a moment for the full analysis.

DIEBOLD NIXDORF, Inc (DBD)

Technology Overvalued low healthy

$82.88

Updated: 2026-06-02

TradeApes Score

Financial Strength

50 Mixed

Operating Trend

55 Mixed

Relative Value

75 Strong

Capital Allocation

55 Mixed

Risk

70 Healthy

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− High P/E — 25–45×, growth premium already priced in

Unlock Full Report →

1 free score card remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.